Investigations The Last Time Moderna's Stock Soared on Vaccine News, Insiders Sold $400 Million. It's Happening Again.
Moderna's stock has run up 137 percent in a month on a melanoma-vaccine trial that has not released its detailed data or reported overall survival. As retail chased the rally, the CEO sold $28.7 million in shares two weeks before the readout, and the rest of the C-suite cashed out after the stock tr
By Marcus Chen · September 18, 2026